At a Glance
- Company: Roche
- Location: Basel, Switzerland
- Headline figures: ARR 0.15 vs 0.18 placebo; two deaths (infections)
- Focus area: Fenebrutinib in relapsing multiple sclerosis (RMS)
- Next steps: Safety data review; EMA/FDA filings planned
What happened?
Roche reported positive topline results from the phase 3 FENhance 1 trial of fenebrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, in relapsing multiple sclerosis on 2 March 2026. The drug met primary endpoints of annualised relapse rate (ARR) reduction and confirmed disability progression, outperforming placebo across both measures.
Why does it matter?
BTK inhibitors offer dual B- and B-cell modulation for superior myelin protection versus current DMTs; fenebrutinib’s brain penetration could address unmet needs in RMS progression. However, two infection-related deaths (one progressive multifocal leukoencephalopathy, one sepsis) raise safety questions versus clean profiles of Ocrevus or Kesimpta, potentially impacting label/uptake in $25B+ MS market.
Who’s behind it?
Roche leads neurology with Ocrevus ($7B+ peak); fenebrutinib targets next-gen oral DMT. Genentech developed the asset through phase 2 proof-of-concept showing 0.12 ARR.
How was it achieved?
FENhance 1 randomised 1,000+ RMS patients to fenebrutinib 200mg BID vs placebo; 96-week data showed 30% ARR reduction (0.15 vs 0.18) and 25% lower disability progression. MRI lesions reduced 85%; safety consistent with phase 2 except fatal events under review.
What’s next?
Full data ASCO or ECTRIMS 2026; regulatory submissions if safety resolves favourably. Fenebrutinib advances in PPMS/nrSPMS trials; Roche assesses risk-benefit vs infection mitigation strategies.
What are people saying?
Roche exec: “Promising efficacy… investigating deaths thoroughly.” Analysts: “Efficacy competitive but safety monitorable; watch infection rates.”